Literature DB >> 11242803

Expression of transforming growth factor beta-1 in chronic hepatitis and hepatocellular carcinoma associated with hepatitis C virus infection.

H G Kim1, Y H Chung, B C Song, J Kim, S H Yang, Y S Lee, D J Suh.   

Abstract

BACKGROUND: Transforming growth factor beta-1 (TGF beta 1) has been suggested to play a role in the development, growth or progression of hepatocellular carcinoma (HCC). Genotype and serum titer of HCV also affect the occurrence of HCC in chronic hepatitis C. In this study, we were to evaluate the effects of genotype or serum titer of HCV on the expression of TGF beta 1. We also intended to examine the correlation between the up-regulation of TGF beta 1 and the association with HCC in patients with chronic hepatitis C.
METHODS: We studied 19 patients with chronic hepatitis C and 18 with HCC associated with HCV infection. HCV genotype was determined by line probe reverse hybridization assay and the amount of HCV-RNA was quantitated by branched DNA signal amplification assay. Serum TGF beta 1 level was measured by enzyme linked immunosorbent assay.
RESULTS: HCV genotypes of patients with HCC were similar to those without it. Serum HCV-RNA titer was higher in genotype 1b than in non-1b (p < 0.05). Serum TGF beta 1 levels were higher in HCC than in chronic hepatitis (p < 0.05). However, there was no significant difference in the serum TGF beta 1 level between genotype 1b and non-1b. Also, it was not correlated with the serum HCV-RNA titer or alanine aminotransferase levels.
CONCLUSION: TGF beta 1 seems to be overexpressed in HCC compared to that of chronic hepatitis C: it was not affected by serum ALT levels, genotype or serum HCV titer. It is suggested that TGF beta 1 may be associated with the malignant transformation of hepatocyte or the progression of HCV-associated HCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11242803      PMCID: PMC4531768          DOI: 10.3904/kjim.2000.15.3.165

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  28 in total

1.  Synergy between transforming growth factor alpha and hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis.

Authors:  J L Jakubczak; F V Chisari; G Merlino
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

2.  An improvement of the single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  C Puissant; L M Houdebine
Journal:  Biotechniques       Date:  1990-02       Impact factor: 1.993

Review 3.  Molecular regulation of hepatic fibrogenesis.

Authors:  E Olaso; S L Friedman
Journal:  J Hepatol       Date:  1998-11       Impact factor: 25.083

4.  Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses.

Authors:  M S Urdea; T Horn; T J Fultz; M Anderson; J A Running; S Hamren; D Ahle; C A Chang
Journal:  Nucleic Acids Symp Ser       Date:  1991

5.  Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

Authors:  M Martinot-Peignoux; P Marcellin; M Pouteau; C Castelnau; N Boyer; M Poliquin; C Degott; I Descombes; V Le Breton; V Milotova
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

6.  Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay.

Authors:  L Stuyver; R Rossau; A Wyseur; M Duhamel; B Vanderborght; H Van Heuverswyn; G Maertens
Journal:  J Gen Virol       Date:  1993-06       Impact factor: 3.891

7.  Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors.

Authors:  R Derynck; D V Goeddel; A Ullrich; J U Gutterman; R D Williams; T S Bringman; W H Berger
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

8.  Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.

Authors:  T Torimura; M Sata; T Ueno; M Kin; R Tsuji; K Suzaku; O Hashimoto; H Sugawara; K Tanikawa
Journal:  Hum Pathol       Date:  1998-09       Impact factor: 3.466

9.  Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers.

Authors:  S Tanaka; K Takenaka; T Matsumata; R Mori; K Sugimachi
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

10.  Transforming growth factor beta 1 promotes spontaneous transformation of cultured rat liver epithelial cells.

Authors:  X Zhang; T Wang; G Batist; M S Tsao
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

View more
  6 in total

1.  MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients.

Authors:  Yousri M Hussein; Fouad E Morad; Magda A Gameel; Wafaa A Emam; Wael H El Sawy; Shereen A El Tarhouny; Eman S Bayomy; Nermin Raafat
Journal:  Med Oncol       Date:  2012-06-01       Impact factor: 3.064

2.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

3.  Liver stem cells and molecular signaling pathways in hepatocellular carcinoma.

Authors:  Krit Kitisin; Michael J Pishvaian; Lynt B Johnson; Lopa Mishra
Journal:  Gastrointest Cancer Res       Date:  2007

Review 4.  Novel therapeutic strategies for targeting liver cancer stem cells.

Authors:  Naoki Oishi; Xin Wei Wang
Journal:  Int J Biol Sci       Date:  2011-04-26       Impact factor: 6.580

Review 5.  Targeting cancer stem cells by using the nanoparticles.

Authors:  In-Sun Hong; Gyu-Beom Jang; Hwa-Yong Lee; Jeong-Seok Nam
Journal:  Int J Nanomedicine       Date:  2015-09-10

6.  Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients.

Authors:  Wafaey M Gomaa; Mohammed A Ibrahim; Mohamed E Shatat
Journal:  Saudi J Gastroenterol       Date:  2014 Jan-Feb       Impact factor: 2.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.